Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by TIXiMED, Inc.

TIXiMED Announces a $2.65M Program-Related Investment from the Helmsley Charitable Trust to Initiate Clinical Trials of Its Novel Oral Therapy for Beta Cell Survival and Function
From TIXiMED, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.